• home
  • about
  • events
  • news
  • members
  • corporate members
  • contact
Join Today
Already a member? Login

Latest Corporate Member News entries

  • Genomic Health – Oncotype DX Colon - 2nd confirmatory Validation Study for Stage II Colon
    Mar 29th, 2012
  • FDA Approval: Important update to the VELCADE(r) (bortezomib) Prescribing Information
    Feb 14th, 2012
  • Effective for dates of service on or after January 1, 2012, the new J-code for both Prolia® and XGEVA® is J0897
    Dec 8th, 2011
  • Important Update: New HCPCS J-Code Effective January 1, 2012
    Dec 8th, 2011
  • Genomic Health Announces Medicare Coverage for Oncotype DX® Colon Cancer Test
    Oct 4th, 2011

<< Back to Corporate Member News

Important Update: New HCPCS J-Code Effective January 1, 2012

Effective January 1, 2012 JEVTANA® has been assigned a HCPCS J-Code:
J9043 Injection, cabazitaxel, 1 mg
by CMS (Centers for Medicare and Medicaid Services).
Click here information for JEVTANA® using the CMS 1500.

Liz
Dec 8th, 2011
Oregon Society of Medical Oncology (OSMO)
Copyright © 2012. All rights reserved.